Clinically, neostigmine is most commonly used as the reversal agent for to the competitive muscle relaxants. Atropine (group 1) and glycopyrrolate (group 2) were studied in doses of 15ug/kg, 20 ug/kg and 77ug/kg, 10ug/kg given intravenously in a mixtu...
Clinically, neostigmine is most commonly used as the reversal agent for to the competitive muscle relaxants. Atropine (group 1) and glycopyrrolate (group 2) were studied in doses of 15ug/kg, 20 ug/kg and 77ug/kg, 10ug/kg given intravenously in a mixture with neostigm-ine 40ug/kg, during operation and at the end of operation 20 ASA class I patients, aged between 15 to 60, were selected in each group.
Anesthesia was maintained with enflurane (1-1.5%), N_2O (2L/min), O_2(2L/min) and pancuronium (50ug/kg) was used as a muscle relaxant.
The results were as fellows :
1) Group 1 showed significant increase and decrease in pulse rate compared with group 2.
2) Atropine-neostigmine mixture significantly showed initial increase and late decrease in pulse rate than glycopyrrolate-neostigmine mixture.
3) In group 2, 20㎍/kg dose of atropine, when administered in a mixture with neostigmine, showed significant initial increase in pulse rate, 15㎍/kg dose of atropine showed significant late bradycardia.
4) In group 2, 7 ㎍/k, 10 ug/kg dose of glycopyrrolate was not associated with initial tachy cardia but late bradycardia was obserred and 10 ㎍/kg dose of glycopyrrolate was associated with more stable heart rate.